Applied Therapeutics Reports Third Quarter 2023 Financial Re

Regulatory submissions on track for govorestat (AT-007) for the treatment of Classic Galactosemia to US FDA and EMA in 4Q 2023Two Upcoming Phase 3...

Related Keywords

Massachusetts , United States , Shoshana Shendelman , Gregory Lewis , Maeve Conneighton , Riccardo Perfetti , Advanz Pharma , James Januzzi , Cardiopulmonary Exercise Testing Laboratory , Twitter , European Association For The Study Of Diabetes , European Medicines Agency , Drug Administration , Expert Forum On Diabetic Cardiomyopathy , Harvard Medical School , Exchange Commission , Marilyn Barry Fellowship In Cardiology Research , Nasdaq , Therapeutics Inc , Classic Galactosemia , Upcoming Phase , Diabetic Cardiomyopathy , Sorbitol Dehydrogenase , Chief Executive Officer , Fourth Quarter , New Drug Application , United States Food , Marketing Authorization Application , Expert Forum , Hutter Family Professor , Marilyn Barry Fellowship , Cardiology Research , Massachusetts General Hospital Gregory Lewis , Section Head , Heart Failure , Massachusetts General , Baseline Data , Ongoing Phase , Diabetes Annual , Annual Meeting , Chief Medical Officer , Applied Therapeutics , Aldose Reductase Inhibitor , Private Securities Litigation Reform Act ,